(0.50%) 5 071.75 points
(0.39%) 38 218 points
(0.64%) 17 550 points
(0.65%) $79.51
(1.19%) $1.955
(0.73%) $2 327.90
(0.25%) $26.82
(1.48%) $969.00
(-0.02%) $0.933
(-0.06%) $11.02
(-0.09%) $0.798
(-0.26%) $93.02
0.00% $ 22.00
Live Chart Being Loaded With Signals
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally...
Stats | |
---|---|
Volumen de hoy | 7 539.00 |
Volumen promedio | 1 786.00 |
Capitalización de mercado | 0.00 |
Last Dividend | $0.204 ( 2022-03-24 ) |
Next Dividend | $0 ( N/A ) |
P/E | 28.95 |
ATR14 | $2.36 (10.72%) |
H. Lundbeck A/S Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
H. Lundbeck A/S Finanzas
Annual | 2021 |
Ingresos: | $16.30B |
Beneficio Bruto: | $12.65B (77.62 %) |
EPS: | $0 |
FY | 2021 |
Ingresos: | $16.30B |
Beneficio Bruto: | $12.65B (77.62 %) |
EPS: | $0 |
FY | 2020 |
Ingresos: | $17.67B |
Beneficio Bruto: | $13.50B (76.42 %) |
EPS: | $7.95 |
FY | 2019 |
Ingresos: | $17.36B |
Beneficio Bruto: | $13.97B (80.50 %) |
EPS: | $13.42 |
Financial Reports:
No articles found.
H. Lundbeck A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.350 | 2013-03-22 |
Last Dividend | $0.204 | 2022-03-24 |
Next Dividend | $0 | N/A |
Payout Date | 2022-04-05 | |
Next Payout Date | N/A | |
# dividends | 8 | -- |
Total Paid Out | $4.94 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.28 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PPWLM | Ex Dividend Junior | 2023-07-19 | Quarterly | 0 | 0.00% | |
EDNMY | Ex Dividend Junior | 2023-06-05 | Annually | 0 | 0.00% | |
UOVEY | Ex Dividend Knight | 2023-08-04 | Annually | 0 | 0.00% | |
KGFHY | Ex Dividend Knight | 2023-10-12 | Annually | 0 | 0.00% | |
BURCA | Ex Dividend Knight | 2023-08-14 | Quarterly | 0 | 0.00% | |
SATLF | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
FIZN | Ex Dividend Knight | 2023-08-14 | Quarterly | 0 | 0.00% | |
YAHOF | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
MCRAA | Ex Dividend Knight | 2023-09-20 | Quarterly | 0 | 0.00% | |
CLZNY | Ex Dividend Knight | 2023-06-09 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0 | 1.500 | -1.111 | -1.667 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.977 | 0.800 | -0.117 | -0.0934 | [1 - 3] |
quickRatioTTM | 0.258 | 0.800 | -3.19 | -2.55 | [0.8 - 2.5] |
cashRatioTTM | 0.258 | 1.500 | 9.68 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 13.14 | 1.000 | 6.25 | 6.25 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.08 | 2.00 | 8.97 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.776 | 1.000 | 0.397 | 0.397 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.123 | 1.000 | 9.53 | 9.53 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 2.41 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0 | 1.000 | -0.101 | 0 | [1 - 100] |
returnOnEquityTTM | 0 | 2.50 | -0.714 | -1.667 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0 | 2.00 | 0 | 0 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.08 | 2.00 | 8.97 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0375 | 1.000 | -1.561 | 0 | [0.1 - 0.5] |
Total Score | 0.155 |
H. Lundbeck A/S
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico